What is ARAD?

It is a national Australian database which collects important health information from individuals with inflammatory arthritis such as:

Rheumatoid arthritis
Ankylosing spondylitis
Juvenile arthritis
Psoriatic arthritis

The aim of ARAD is to determine effectiveness and safety of new biological drugs used to treat inflammatory arthritis condition, such as Enbrel, Remicade, Humira, Kineret, MabThera and Orencia.
ARAD collects information from patients every 6 months via questionnaires. Questions about medical history, medication history, responses to medication, physical functioning and quality of life are included.
Patients and rheumatologists across Australia contribute to ARAD.

Further details in the Participant Brochure

The benefits of participating in and supporting ARAD

ARAD provides a valuable resource for all patients with this chronic disease and their clinicians by monitoring individual patient outcomes and adverse events.
Annual reports are provided to participating rheumatologists with the progress of their own patients as well as comparing their patients to the ARAD population.
Information on the ARAD population is provided to participants, clinicians, researchers and policy makers. This is combined information only and contains nothing that would allow an individual to be identified.
Regular newsletters are provided to participants updating them with information about ARAD. Click here for all newsletters.

Currently funded by: Unrestricted educational grants from Pfizer Pty Ltd, Bristol-Myes Squibb Pty Ltd and AbbVie Pty Ltd administered through the ARA

Supported by:
Monash University
Cabrini Health

with additional funding through Educational Grants to the ARA from:
Abbott Australasia Pty Ltd
Pfizer Pty Ltd
MSD

previous educational grants were provided to the ARA by:
Amgen Australia Pty Ltd
Aventis
Roche Products Pty Ltd
MSD
Monash University
Cabrini Healt

What is ARAD?

The benefits of participating in and supporting ARAD

Click for easy access: